Izalontamab targets both EGFR and HER3 and was shown to have an ORR of up to 64.3% when combined with taxanes in R/M HNSCC patients who had progressed on prior immunotherapy but were naïve to platinum-based chemotherapies [23]. Here, EGFR is linked to head and neck squamous cell carcinoma.